HUMAN PAPILLOMAVIRUS (HPV) AND CYTOMEGALOVIRUS (CMV) THERAPEUTICS MARKET ANALYSIS
The global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market was valued at US$ 3,006.4 million in 2018, and is expected to witness a CAGR of 6.0% during the forecast period (2018– 2026).
Figure 1. Global Human Papillomavirus (HPV) and (CMV) Cytomegalovirus Therapeutics Market Value Analysis (US$ Mn) and Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2019)
Increasing number of sexually transmitted infections is expected to drive growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market
Increasing number of sexually transmitted infections is one of major drivers for the market growth. For instance, according to World Health Organization’s (WHO) report in 2019, over 290 million women suffer from HPV infection worldwide, annually and over 1 million people suffer from sexually transmitted infections (STIs) every day, worldwide.
Moreover, increasing approvals for vaccines is expected to boost the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth. For instance, in October 2018, the U.S Food and Drug Administration (FDA) approved Gardasil 9 ( HPV 9-valent vaccine), developed by Merck & Co., Inc. Gardasil 9 is used for cervical, vulvar, vaginal, and anal cancers caused by HPV types.
Figure 2: Global Human Papillomavirus (HPV) and (CMV) Cytomegalovirus Therapeutics Market Value (US$ Mn), By Region, 2018
Source: Coherent Market Insights Analysis (2019)
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowPress Release
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
